153 related articles for article (PubMed ID: 10516606)
1. Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy.
Jacobberger JW; Sramkoski RM; Zhang D; Zumstein LA; Doerksen LD; Merritt JA; Wright SA; Shults KE
Cytometry; 1999 Oct; 38(5):201-13. PubMed ID: 10516606
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
3. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells.
Shimada H; Liu TL; Ochiai T; Shimizu T; Haupt Y; Hamada H; Abe T; Oka M; Takiguchi M; Hiwasa T
Oncogene; 2002 Feb; 21(8):1208-16. PubMed ID: 11850840
[TBL] [Abstract][Full Text] [Related]
4. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
Mu Z; Hachem P; Agrawal S; Pollack A
Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
[TBL] [Abstract][Full Text] [Related]
5. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
6. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
[TBL] [Abstract][Full Text] [Related]
7. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.
Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG
Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
9. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
Meng RD; Shih H; Prabhu NS; George DL; el-Deiry WS
Clin Cancer Res; 1998 Jan; 4(1):251-9. PubMed ID: 9516979
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
11. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
12. The role of natural killer cells in adenovirus-mediated p53 gene therapy.
Carroll JL; Nielsen LL; Pruett SB; Mathis JM
Mol Cancer Ther; 2001 Nov; 1(1):49-60. PubMed ID: 12467238
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.
Ohtani S; Kagawa S; Tango Y; Umeoka T; Tokunaga N; Tsunemitsu Y; Roth JA; Taya Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2004 Jan; 3(1):93-100. PubMed ID: 14749479
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
15. Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro.
Wu Q; Kreienberg R; Runnebaum IB
J Cancer Res Clin Oncol; 2000 Mar; 126(3):139-44. PubMed ID: 10741907
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-based p53 gene therapy in ovarian cancer.
Santoso JT; Tang DC; Lane SB; Hung J; Reed DJ; Muller CY; Carbone DP; Lucci JA; Miller DS; Mathis JM
Gynecol Oncol; 1995 Nov; 59(2):171-8. PubMed ID: 7590467
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
18. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells.
Yang HL; Dong YB; Elliott MJ; Wong SL; McMasters KM
Cancer Gene Ther; 2001 Apr; 8(4):241-51. PubMed ID: 11393276
[TBL] [Abstract][Full Text] [Related]
19. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
Yang HL; Dong YB; Elliott MJ; Liu TJ; Atienza C; Stilwell A; McMasters KM
Clin Cancer Res; 1999 Aug; 5(8):2242-50. PubMed ID: 10473112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
